Cargando…
Clinically feasible stratification of 1-year to 3-year post-myocardial infarction risk
OBJECTIVE: Post-myocardial infarction (MI) care is crucial to preventing recurrent major adverse cardiovascular events (MACE), but can be complicated to personalise. A tool is needed that effectively stratifies risk of cardiovascular (CV) events 1–3 years after MI but is also clinically usable. METH...
Autores principales: | Horne, Benjamin D, Muhlestein, Joseph B, Bhandary, Durgesh, Hoetzer, Greta L, Khan, Naeem D, Bair, Tami L, Lappé, Donald L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845421/ https://www.ncbi.nlm.nih.gov/pubmed/29531761 http://dx.doi.org/10.1136/openhrt-2017-000723 |
Ejemplares similares
-
A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL(3)+IDL])
por: May, Heidi T, et al.
Publicado: (2013) -
Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction
por: Clark, James, E, et al.
Publicado: (2018) -
The cost of inpatient death associated with acute coronary syndrome
por: Page, Robert L, et al.
Publicado: (2016) -
Frequency and Outcomes of Patients Presenting with Non-ST Elevation Myocardial Infarction (NSTEMI) without Standard Modifiable Risk Factors: A US Healthcare Experience
por: Anderson, Jeffrey L., et al.
Publicado: (2023) -
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
por: Woxholt, Sindre, et al.
Publicado: (2023)